Nektar presents rezpegaldesleukin data at dermatology meeting

March 28, 2026 12:36 PM

Nektar Therapeutics (NASDAQ: NKTR) presented data from two Phase 2b studies of its drug rezpegaldesleukin at the 2026 American Academy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found